This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Advocacy Campaigns
CCA works to advocate for the IBD community in a range of ways:
- Lobbying governments for funding
- Providing submissions about health policy
- Raising consumer needs to researchers and industry
- Awareness campaigns
Current advocacy campaigns
Help improve the quality of life for regional Australians living with chronic inflammatory conditions
Closed 2022
Review of the National Medicines Policy
Closed October 2021.
Have your say on PBS listings for IBD Medications
The Pharmaceutical Benefits Advisory Committee (PBAC) is seeking consumer feedback on IBD medications which are being considered for PBS listing. If you would like to provide feedback on a USTEKINUMAB biosimilar medicine (Steqeyma®), and BUDESONIDE Suppository 4 mg (Budenofalk®) then send us an email about what difference it has made/would make to your life to [email protected]. We will then forward all comments consolidated to PBAC. The closing date for comments to CCA is 23 September 2024.
| Drug Name, form(s), strength(s) and Sponsor, Submission type (Drug name, form, strength, Trade name®, Sponsor, new listing/change to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |
| BUDESONIDE Suppository 4 mg Budenofalk® DR FALK PHARMA AUSTRALIA PTY LTD (New PBS listing) | Ulcerative colitis | To request a General Schedule Unrestricted Benefit listing of a new form for the short-term treatment of mild to moderate ulcerative colitis limited to the rectum. |
| USTEKINUMAB Injection 45 mg in 0.5 mL single use pre-filled syringe Injection 90 mg in 1 mL single use pre-filled syringe Solution for I.V. infusion 130 mg in 26 mL Steqeyma® CELLTRION HEALTHCARE AUSTRALIA PTY LTD (New PBS listing) | Severe chronic plaque psoriasis Severe psoriatic arthritis Severe Crohn disease Complex refractory fistulising Crohn disease | To request General Schedule and Section 100 (Highly Specialised Drugs Program) listings of an ustekinumab biosimilar for the treatment of severe chronic plaque psoriasis, severe psoriatic arthritis, severe Crohn disease, and complex refractory fistulising Crohn disease. |
For information about the PBS meeting visit the PBAC meeting page on the PBS website.